Yen-Hung Chow

Prof. Dr. Yen-Hung Chow


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Vaccine
Verified
Journal Article
Closed access
NCNai-Hsiang Chung
Nai-Hsiang Chung
YCYing-Chin Chen
Ying-Chin Chen
SYShiu-Ju Yang
Shiu-Ju Yang
YLYu-Ching Lin
Yu-Ching Lin
HDHorng Yunn Du
Horng Yunn Du
YCYen-Hung Chow
Yen-Hung Chow

27 July 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
HCHuai-Chia Chuang
Huai-Chia Chuang
CHChia‐Hsin Hsueh
Chia‐Hsin Hsueh
PHPu‐Ming Hsu
Pu‐Ming Hsu
RHRou‐Huei Huang
Rou‐Huei Huang
CTChing‐Yi Tsai
Ching‐Yi Tsai
Tse-Hua TanTse-Hua Tan
Tse-Hua Tan
ACE2 on epithelial cells is the SARS‐CoV‐2 entry receptor. Single‐cell RNA‐sequencing data derived from two COVID‐19 cohorts revealed that MAP4K3/GLK‐positive epithelial cells were increased in patients. SARS‐CoV‐2‐induced GLK overexpression in epithelial cells was correlated with COVID‐19 severity and vesicle secretion. GLK overexpression induced the epithelial cell‐derived exosomes containing ACE2; the GLK‐induced exosomes transported ACE2 proteins to recipient cells, facilitating pseudovirus infection. Consistently, ACE2 proteins were increased in the serum exosomes from another COVID‐19 cohort. Remarkably, SARS‐CoV‐2 spike protein‐stimulated GLK, and GLK stabilized ACE2 in epithelial cells. Mechanistically, GLK phosphorylated ACE2 at two serine residues (Ser776, Ser783), leading to the dissociation of ACE2 from its E3 ligase UBR4. Reduction in UBR4‐induced Lys48‐linked ubiquitination at three lysine residues (Lys26, Lys112, Lys114) of ACE2 prevented its degradation. Furthermore, SARS‐CoV‐2 pseudovirus or live virus infection in humanized ACE2 mice induced GLK and ACE2 protein levels, and ACE2‐containing exosomes. Collectively, ACE2 stabilization by SARS‐CoV‐2‐induced MAP4K3/GLK may contribute to the pathogenesis of COVID‐19.

24 March 2023 in Virus Research
Verified
Journal Article
Open access
SLSheng-Chieh Lien
Sheng-Chieh Lien
YSYu-Sheng Shen
Yu-Sheng Shen
HLHsiao-Yu Lin
Hsiao-Yu Lin
SWShang-Rung Wu
Shang-Rung Wu
CFChih-Yeu Fang
Chih-Yeu Fang
CLChia-Chyi Liu
Chia-Chyi Liu
• Many coxsackievirus A10 isolates have low culture efficiency in vero cells. • HEK293A cell is a suitable cell line for coxsackievirus A10 propagation. • A serum-free HEK293A cell culture was developed for coxsackievirus A10 production. • Other enteroviruses could also be propagated in serum-free HEK293A cell culture.

17 August 2022 in Journal of Chromatography A
Verified
Journal Article
Closed access
SLSheng-Chieh Lien
Sheng-Chieh Lien
CLChia-Chun Lu
Chia-Chun Lu
YSYu-Sheng Shen
Yu-Sheng Shen
YYYa-Ting Yang
Ya-Ting Yang
SWShang-Rung Wu
Shang-Rung Wu
CLChia-Chyi Liu
Chia-Chyi Liu

28 October 2023 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
YSYu-Sheng Shen
Yu-Sheng Shen
YCYen-Hung Chow
Yen-Hung Chow
CFChih-Yeu Fang
Chih-Yeu Fang
SWShang-Rung Wu
Shang-Rung Wu
CCChi-Hsun Chen
Chi-Hsun Chen
CLChia-Chyi Liu
Chia-Chyi Liu
Vaccine stability is an important issue for vaccine development, which affects whether the vaccine product is effective within a certain period of time in each progress. Hand, foot, and mouth diseases (HFMD) is an epidemic disease in young children usually caused by Enterovirus A group viruses, and the Enterovirus A71 (EV-A71) had caused several pandemics and public health issues around the world. After two decades of research and development, formalin-inactivated EV-A71 (FI-EV-A71) vaccines are the first to complete the phase III clinical trials for protection against EV-A71 infection. Currently, the shelf life of FI-EV-A71 vaccine product is set to be within 18 months, but the stability and the effectiveness of the FI-EV-A71 whole virion when stored long-term at low temperature remains undetermined. Assessing the long-term storage properties of viral particles facilitates flexibility in manufacturing of vaccine products. In this study, the stability profiles of FI-EV-A71 vaccine lots and bulks after long-term of low temperature storage were analyzed by protein tests, particle measurement and animal immunization study. After over ten years of storage, the reduction of protein concentration in the FI-EV-A71 bulk samples is less than 30 % and the antigenic content remained in a suspended, particulate state. Both the packed FI-EV-A71 final vaccine products and the FI-EV-A71 antigens adjuvant premix bulk could elicit strong neutralizing responses in mice. After ten years of low temperature storage, the FI-EV-A71 vaccine still presents decent stability and good immunogenicity.

8 April 2023 in Viruses
Verified
Journal Article
Open access
PDF file
SYShu Ling Julian Yu
Shu Ling Julian Yu
NCNai-Hsiang Chung
Nai-Hsiang Chung
YLYu-Ching Lin
Yu-Ching Lin
YLYi-An Liao
Yi-An Liao
YCYing-Chin Chen
Ying-Chin Chen
YCYen-Hung Chow
Yen-Hung Chow
Coxsackievirus A10 (CVA10) causes hand, foot, and mouth disease (HFMD) and herpangina, which can result in severe neurological symptoms in children. CVA10 does not use the common enterovirus 71 (EV71) receptor, human SCARB2 (hSCARB2, scavenger receptor class B, member 2), for infection but instead uses another receptor, such as KREMEN1. Our research has shown that CVA10 can infect and replicate in mouse cells expressing human SCARB2 (3T3-SCARB2) but not in the parental NIH3T3 cells, which do not express hSCARB2 for CVA10 entry. Knocking down endogenous hSCARB2 and KREMEN1 with specific siRNAs inhibited CVA10 infection in human cells. Co-immunoprecipitation confirmed that VP1, a main capsid protein where virus receptors for attaching to the host cells, could physically interact with hSCARB2 and KREMEN1 during CVA10 infection. It is the efficient virus replication following virus attachment to its cellular receptor. It resulted in severe limb paralysis and a high mortality rate in 12-day-old transgenic mice challenged with CVA10 but not in wild-type mice of the same age. Massive amounts of CVA10 accumulated in the muscles, spinal cords, and brains of the transgenic mice. Formalin inactivated CVA10 vaccine-induced protective immunity against lethal CVA10 challenge and reduced the severity of disease and tissue viral loads. This is the first report to show that hSCARB2 serves as an associate to aid CVA10 infection. hSCARB2-transgenic mice could be useful in evaluating anti-CVA10 medications and studying the pathogenesis induced by CVA10.